• Health and wellness drug product innovator Lexaria Bioscience has developed a patented technology — DehydraTECH (TM) — which enhances the bioavailability of fat-soluble drugs and molecules
• Lexaria continues to research DehydraTECH’s ability to improve the speed and bioavailability of cannabidiol (“CBD”) in treating high blood pressure and epileptic conditions
• The company continues its research demonstrating the ability of its technology -to enhance the performance of antiviral drugs and other active pharmaceutical ingredients
• Sublicensing DehydraTECH continues to create revenues for the company
• Lexaria has additionally pursued the use of its drug-enhancing technology, in partnership with sublicensees, for making adult-use recreational cannabis more effective

The potential for drug innovator Lexaria Bioscience’s (NASDAQ: LEXX) patented DehydraTECH(TM) technology to transform the pharmaceutical industry continues to display itself in clinical trials and licensing deals that advance use and awareness of the technology. The company recently announced it has begun animal research to compare effectiveness of FDA-approved Epidiolex to DehydraTECH-CBD for reducing seizure activity. Epidiolex, the world’s only cannabidiol (“CBD”)-based seizure medication to gain approval from the U.S Food and Drug Administration (“FDA“) for treating epileptic conditions (https://ibn.fm/4iZar). Lexaria has analyzed DehydraTECH-enhanced CBD in a variety of applications, the idea being that if DehydraTECH-CBD can enter the bloodstream more rapidly and more potently than CBD that hasn’t been enhanced, then Lexaria can establish the potential benefits of its IP for improving drugs trademarked by other companies. That in turn opens the door to the possibility of high-profile brand-name drugs becoming more effective at lesser dosages, and therefore less expensive as a result. The most immediate benefits in DehydraTECH enhancement are that treated drug products are utilized by the body faster, without any troubling side effects, and that DehydraTECH’s ability to mask any unpleasant tastes eliminates the need to use sweeteners to make the drugs palatable. The technology combines active pharmaceutical ingredients (“APIs”) with a fatty acid oil, applies it to a target compound such as CBD, synthesizes it via a dehydration process and markets the final product as something that can be consumed or combined with a liquid or, in some applications, powders. Reduced filtration by the body’s digestive system makes the product more effective in its use. One marked area of study announced by the company in addition to the new Epidiolex research includes human studies of DehydraTECH-CBD in reducing high blood pressure and potentially being used to treat heart disease (https://ibn.fm/9Fg2g). In non-CBD applications, the DehydraTECH technology has been studied as a means of enhancing the assimilation speed and effectiveness of orally ingested (not inhaled) nicotine, erectile dysfunction drugs such as Viagra and antiviral drugs such as Remdesivir, Ebastine and Colchicine, used in treating COVID-19 patients during the ongoing global pandemic. Each of the research projects has reported astoundingly positive results thus far (https://ibn.fm/znCnN). “Lexaria has a successful track record through strategic partners and licensees who use DehydraTECH technology and have demonstrated improved delivery and performance of tetrahydrocannabinol (“THC”) in both subjective human studies and marketed consumer packaged goods product offerings,” the company stated last year (https://ibn.fm/NMFZl). Lexaria has repeatedly demonstrated that DehydraTECH-processed CBD has superior delivery characteristics into the bloodstream and brain compared to generic CBD and has evidenced similar results with THC. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

On April 5, 2020, beginners, advocates (anyone interested in moving the real estate blockchain space forward), and professionals making a mark in the real estate sector – developers, brokers, traders, policymakers, financiers, startups, and agents – will congregate at the magnificent Hilton Miami Airport Blue Lagoon hotel for the reBLOCKmiami event, set to run from 8.30 am through 5.00 pm. The goal is to learn and network, focused on real estate blockchain, tokenization, non-fungible tokens (“NFTs”), and fintech startups, as well as Decentralized Finance (“DeFi”) real estate, regulatory updates, tradeable private real estate, and buying property in the metaverse. The one-day reBLOCKmiami event will feature more than 25 speakers who currently hold or previously held executive positions in their respective organizations. It also includes a roster of leaders from different associations and governmental bodies, such as Elena Bondarenko, the Government Relations Counsel at Miami Downtown Development Authority, Samuel Armes from the Florida Blockchain Business Association (“FBBA”), and Vince Lago, the Mayor of Coral Gables, Florida. Vince, alongside the Former VP of Hialeah City Council Oscar A. De la Rosa, will at 8.30 am start things off with a presentation dubbed “Morning with the mayors: The vision for crypto and future development.” Their session will kick-start a series of 30-minute talks (presentations and panel discussions), staggered throughout the day, discussing various topics. These include “The future of real estate development in Miami,” “Unlocking liquidity by tokenizing real estate,” “Women in real estate blockchain: Innovating real estate one NFT at a time,” “Bringing tokens to market: From start to finish,” “Regulation: NFTs, digital assets, & real estate,” and more. For a complete list of the scheduled sessions, check out the event plan at (https://ibn.fm/fWPmW). To mark the end of the fulfilling full day of learning, the organizers have scheduled a 1-hour meet-and-greet session between 5.00 pm and 6.00 pm, during which attendees will get a chance to network with their peers and the speakers, exchanging knowledge of the marriage between real estate and crypto/blockchain/DeFi. Thereafter, DJ WildStyle will work the turntables to ensure attendees find their way to the dancefloor at the poolside after-party. The reBLOCKmiami event promises to be a blend of knowledge acquisition, networking opportunities, and fun. The event will officially kick start a series of crypto and blockchain events in Miami set for April 5 to 10 (https://ibn.fm/yySkp). To purchase your ticket, please visit https://reblockmiami.com/tickets/ (different packages are available). For more information on the event, please visit the official website at https://reblockmiami.com. 

• The partnership will see the rebranding of XMarket brick-and-mortar stores in Venice, and Hillcrest, California, under the BESTIES brand
• PlantX is confident that its partnership with BESTIES will accelerate the already significant growth for PlantX
• In the first month of the rebrand, PlantX posted a 30% growth in sales revenue

Over the past year, PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) has embarked on an aggressive expansion campaign to strengthen its retail footprint and bring its products and services closer to consumers. This has seen the opening of various XMarket brick-and-mortar stores in strategic locations, the launch of shop-in-shops within Hudson’s Bay locations, and the acquisition of key brands in the vegan space. In a move that seeks to strengthen its presence in this industry further, PlantX has just announced its retail partnership with BESTIES Vegan Paradise. BESTIES is a leading enterprise in the plant-based space, providing a platform for independent, vegan businesses to contribute to expanding the vegan community (https://ibn.fm/yX9aU). Launched in 2019 by Asia Phoenix and Matt Fontana, BESTIES has grown into one of the key movers in the plant-based space. Through its innovation and its push to enable a plant-based lifestyle among consumers, it has been awarded “Best Grocery Store” in the VegNews Veggie Awards for two consecutive years. PlantX is confident that this partnership will further both companies’ goals to propel plant-based accessibility for all. “Both PlantX and I, personally, are committed to the values and ethics that Asia, Matt, and the BESTIES brand have come to epitomize in the vegan community,” noted Sean Dollinger, the Founder of PlantX. “This partnership will no doubt accelerate the already massive growth for PlantX as we confirm our commitment to those values and cement our place as a leader in the ethical vegan marketplace,” he added. This collaboration with BESTIES has seen PlantX begin redesigning and rebranding its XMarket brick-and-mortar stores in Venice, California, and Hillcrest, California, under the BESTIES brand. In addition, these locations will stock BESTIES branded products such as vegan soft serve. They will also allow orders placed on its e-commerce stores, with same-day deliveries across Los Angeles and San Diego. “We are very thankful to be working so closely with the founders of BESTIES, Matt Fontana and Asia Phoenix, who recognize PlantX as a leader in the vegan space,” said Lorne Rapkin, the Chief Executive officer (“CEO”) of PlantX. “With the knowledge that they too, are industry leaders and want to join forces to roll out their brand with our support is very powerful,” he added. Following this partnership, PlantX has reported an additional 30% in sales revenue for the first month since the Venice location was rebranded to reflect the BESTIES model. In addition, the company’s management is confident that sales will continue increasing, having tapped into a more recognized brand in the plant-based space. For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

Noble Capital Markets has announced that Rob Goldman will be a featured Metaverse panelist at NobleCon18, which feature presentations from 120 public companies on April 20 and 21 at The Guitar Hotel near Miami, FL. Joining Facebook (NASDAQ: FB) in 2012 reporting directly to CEO Mark Zuckerberg, Goldman was charged with growing and monetizing the burgeoning social media platforms (including subsidiaries such as Instagram). During his tenure at Facebook, revenues grew from $5 billion to over $70 billion in a span of seven years. Goldman’s move to Facebook happened when his company, Threadsy, was acquired by the social media giant in a move that many refer to as one of “Mark Zuckerberg’s acqui-hires.” Goldman’s company started out as a way for people to see their social feeds and communication from different networks, like Facebook and Twitter, in one place. But Goldman soon changed the focus towards a paid service that helped brands see which influencers they needed to establish relationships with in order to find new customers on social networks. The change resulted in the development of the social marketing tool Swaylo, which ultimately attracted the attention of Zuckerberg. Mr. Goldman is a graduate of Harvard Business School. Admission to NobleCon is free for all levels of investors from self-directed novices to institutional investors, thanks to Noble, Channelchek, Sponsors and The Presenting Companies. Attendance is limited to 1,000. To secure a ticket, visit https://nobleconference.com/register/investor-guest Full list of speakers: https://channelchek.com/news-channel/Scheduled_Speakers_NobleCon18 The presenting companies: https://channelchek.com/news-channel/NobleCon18_Presenting_Companies

• RWB’s mission has always been to become the superior and most recognizable cannabis company in the United States
• It seeks to achieve this by focusing on the continued growth of top-line revenue and bottom-line results through brand expansion, mergers, and acquisitions
• So far, in 2022, the company has announced the acquisition of PharmaCo, which sees the transfer of 21 medical and adult-use cannabis licenses
• RWB has also closed a lease assignment on a critical manufacturing/processing and distribution facility in Michigan
• Its management is confident that the foundations laid down so far will aid in the company’s growth going forward

In 2020, Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) set out on a three-year plan for success. The initial strategy was to form a solid foundation to define its identity while cementing its position in crucial states within the United States. So far, the company has set base in Michigan, Florida, California, and Illinois, in what marks an aggressive and successful expansion plan. “For the balance of 2021 and throughout 2022, the company will focus on the continued growth of our top-line revenue and bottom-line results through expansion of our house of brands that continue to gain momentum, fortification of our vertically integrated businesses, and the synergies from our M&A success,” noted Brad Rogers, the Chairman and Chief Executive Officer (“CEO”) of the company (https://ibn.fm/b9Tf0). In line with these goals and projections, RWB announced the acquisition of PharmaCo, in a transaction initially announced back on July 27, 2020. The purchase sees the transfer of 21 medical and adult-use cannabis licenses to RWB. Additionally, the company now has access to eight fully-operating dispensaries, two operational indoor cultivation facilities, one municipality licensed 10-acre outdoor cultivation facilities, and 22 owned properties for potential additional cultivation and dispensary locations, among others (https://ibn.fm/crX2V). “I’m pleased to announce that we have closed on the PharmaCo acquisition and now control all aspects of our Michigan operations,” noted Mr. Rogers. “This is a major milestone for RWB and its shareholders as we continue to execute key components of our growth strategy and build our house of brands across our core markets, as promised. We are now in the driver’s seat on over 20 assets across Michigan- one of the largest and fastest-growing cannabis markets in the country,” he added. At the beginning of the 2022 calendar year, RWB also closed on a lease assignment for a 15,000 square foot manufacturing/processing and distribution facility in Warren, Michigan. The property already has both medical and adult-use licenses, which allow RWB to begin manufacturing medical and adult-use cannabis products while leveraging a centralized distribution that the existing infrastructure provides (https://ibn.fm/OL1ly). This move also saw RWB’s expansion of its Platinum Vape products and the strengthening of its human resources following the hiring of 30 full-time employees with the objective of growing the number to 50 over the course of the year. Additionally, at the close of the 2021 calendar year, RWB settled a CAD$5.1 million debt and refinanced a CAD$12.8 million acreage Florida acquisition note. It also announced a $6 million year-over-year increase in revenue for the third quarter of the 2021 financial year, representing a 93% growth. In a statement from Mr. Rogers, he noted: “In the third quarter, we made excellent progress in laying additional building blocks in our core operating states of Florida, Michigan, and California to become more vertically integrated where it will be most profitable” (https://ibn.fm/YAyla). The company remains optimistic that the upward trajectory in growth and performance will carry on throughout the 2022 calendar year. The foundations laid down so far line up with the company’s goals and objectives as it gains momentum and fortifies its vertically integrated businesses. For more information, visit the company’s website at www.RedWhiteBloom.com. NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://ibn.fm/RWBYF

• In a video message to shareholders, CEO John Climaco detailed the operational and clinical progress made by lead drug candidate Berubicin despite market volatility and share price fluctuations
• CNS is currently enrolling patients into a potentially pivotal global drug trial of Berubicin for recurrent glioblastoma multiforme
• Interim analysis of the trial is currently expected as early as the first quarter of 2023, once 30-50% of trial patients have been on the study for six months

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotech company specializing in developing novel treatments for primary and metastatic cancers of the brain and central nervous system, has released a video to its shareholders that reiterates the operational and clinical progress of its lead drug candidate, Berubicin. The video features CNS CEO John Climaco and addresses the recent share price activity (https://ibn.fm/Z40Gw). “The divergence that exists between our operational strength and share price is top of mind for myself and the whole team at CNS Pharmaceuticals. As a shareholder of CNS Pharma, I share in the frustrations as it pertains to the share price and fluctuation in the market – both of which are things out of our control,” Climaco said in his video message. “However, as the CEO, what I do have control over is executing on the day-to-day operations, which I want to reiterate and emphasize have simply never been stronger.” Climaco went on to detail the company’s operational strengths, including the fact that it continues to enroll patients in its potentially pivotal global study of Berubicin in the treatment of adult glioblastoma multiforme (“GBM”). “We have the leading minds in the field around the world working on this trial with us, and we have encouraging ongoing dialogue with the FDA to ensure that our potentially pivotal trial continues to represent the state-of-the-art in the field,” he said. The CNS CEO also underlined that his company remains committed to continuing to execute its operational excellence to drive recognition in the market of Berubicin and its immense potential for patients – the key driver for ultimately generating shareholder value and tremendous hope for GBM patients worldwide. “We put our heads down every day and continue to charge forward in our mission to change the game in glioblastoma via Berubicin,” Climaco added. The video comes days after the company released its full-year 2021 financial results and corporate update, highlighting key milestones during the previous year, including (https://ibn.fm/Lb1r3):

• May 2021 – Beginning of patient enrollment for a potentially pivotal global study evaluating the efficacy of Berubicin for adult recurring GBM
• June 2021 – Granting of Fast Track Designation by the FDA for recurrent GBM treatment with Berubicin
• September 2021 – First patients from potentially pivotal study dosed with Berubicin
• December 2021 – Approval from “swissethics,” the umbrella organization of the Ethics Committee (“EC”) in Switzerland, for the potentially pivotal study of Berubicin for treatment of recurrent GBM to proceed in Switzerland
• January 2022 – Announcement of $11.5 million private placement, priced at the market under NASDAQ rules

CNS plans to expand the potentially pivotal study of Berubicin in recurrent GBM into additional countries and complete the enrollment needed for the interim analysis of the study within the year. The interim analysis of the trial will occur when 30-50% of the total expected patients have been on the study for at least six months, which is anticipated during the first half of 2023. Berubicin is a novel anthracycline and the first that appears to cross the blood-brain barrier. It is currently in development for the treatment of a number of serious brain and oncology indications. The first trial of the drug was initiated by Reata Pharmaceuticals over 16 years ago. It resulted in one patient surviving cancer-free, and two others reporting a reduction in tumor size of up to 80%. For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Cannabis sales in Colorado broke another record last year, topping $2.22 billion in products sold
• Cannabis is “massive” driver of tax revenue for Colorado, raking in over $423 million last year alone
• HENC continues to pursue diversification and integration strategy through subsidiary

Another record-breaking year for Colorado’s cannabis industry bodes well for Hero Technologies (OTC: HENC). The company anticipates expanding into the booming market via cultivation and dispensary operations through its wholly owned subsidiary, Mile High Green LLC. Cannabis sales in the state broke another record last year, topping $2.22 billion in products sold, according to the Colorado Department of Revenue (https://ibn.fm/NNChl). This figure “eclipses” 2020 sales reaching upwards of $2.1 billion, which set a previous record, reported a recent “CPR News” article (https://ibn.fm/uSmIo). “Peter Marcus, a spokesperson for the recreational and medical cannabis dispensary chain Terrapin Care Station, wasn’t surprised when he saw the latest numbers from the state,” the article noted. “Popularity for cannabis has only grown since the state-licensed retail sales of the plant in 2014, he said. Plus, 2021, just like its predecessor, was filled with pandemic anxiety.” The article quoted Marcus, who stated, “We find during crises times that people tend to turn to relief, and previously it had been alcohol. I think having this legal alternative was a significant shift for people. What we learned from the pandemic is that cannabis is more or less recession-proof.” According to “CPR News,” cannabis sold by both medical and retail cannabis stores has totaled more than $12.2 billion since the state began tracking cannabis sales in January 2014. “Retail cannabis made up the vast majority of last year’s sales, approximately 82% or $1.82 billion of the $2.22 billion,” the article noted. “Business peaked in March 2021 when retailers brought in more than $207 million that month. “Cannabis is a massive driver of tax revenue for Colorado, raking in over $423 million last year alone and upwards of $2 billion since 2014 in sales and excise taxes and fees,” the CPR article continued. “It’s also a big employer. According to an annual Leafly report, over 35,500 Coloradans worked in the cannabis industry in 2021.” Hero Technologies announced the formation of Mile High Green in March of last year, stating that the purpose of the subsidiary was to seek cannabis license, land purchase and strategic acquisition opportunities in the state of Colorado (https://ibn.fm/DeXf4). “By establishing another subsidiary to target cannabis property acquisitions and cannabis licenses, we continue to aggressively pursue our diversification and integration strategy,” said Hero Technologies CEO Gina Serkasevich. “Colorado is an obvious market for us to target for expansion. It was exciting to see the state’s cannabis sales soar to $2.2 billion in 2020, truly an all-time high. We will work hard to gain market share in this important territory and participate in its healthy growth.” Hero Technologies is a cannabis company working toward a vertically integrated business model. The company owns a majority stake in BlackBox Systems and Technologies LLC, an aeroponic cannabis cultivation system that provides optimal growing conditions to enhance photosynthesis and cultivation of large flowering plants, creating increased harvest efficiencies. The company’s strategic business plan includes cannabis genetic engineering, farmland for both medical and recreational cannabis cultivation, production licenses, distribution licenses, consumer packaging, and retail and dispensary operations that make the company a multistate operator. For more information, visit the company’s website at www.HeroTechnologiesInc.com. NOTE TO INVESTORS: The latest news and updates relating to HENC are available in the company’s newsroom at https://ibn.fm/HENC

• Company SEC filing outlines company mission, unique differentiation
• Company uses ML, NL processing to comprehend huge amounts of data thousands of times faster than humans with significantly reduced errors, more objectivity
• Pluaris is a subscription-based SaaS product platform that adapts to user needs

Almost a decade ago, Nowigence Inc. (NOWG) started on its mission to create an artificial intelligence software platform that could read and comprehend data. Today, the company is proud to offer Pluaris, a cloud-based app that automates reading and analysis of textual data so users can learn more in less time, uncover hidden insights and stay on top of the information they need to know. Nowigence’s focus has expanded since those formative early years. Its filing with the Securities Exchange Commission (“SEC”) states that Nowigence is committed to create an AI platform to rapidly read and comprehend data using machines, whether unstructured or structured, in the data’s right context and provide business professionals with a toolkit to anticipate their future through data, predict scenarios, and keep plan-ready, united and confident to meet their business goals (https://ibn.fm/1EGYc). “Any technology-based solution is successful if it increases speed while reducing error,” the filing continues. “In our case, we use machine learning and natural language processing to comprehend huge amounts of data in real time many thousands of times faster than human abilities with significantly reduced errors and larger objectivity.” Pluaris is built around a unique differentiation. “Our view of the market is that AI using ML/NLP techniques is currently a project-based service industry,” the company states. “Clients hire coding engineers, data scientists and project managers to scope the requirements of a specific use case in the form of technical specs, which is then converted into a solution. This consultancy-based approach is not scalable. From a customer’s perspective, it is expensive, time consuming and does not guarantee success.” Seeking to provide a scalable alternative, Nowigence created Pluaris, a subscription-based SaaS product platform that adapts to the needs of its users. Designed to work across different functions and sectors, Pluaris is easy to learn, allowing users to customize, work with and benefit from the product from day one. Another unique aspect of Nowigence’s unique offering is that Pluaris is one of only a few solutions that allow users direct access to the database. “Most other cognitive information retrieval engines allow access from an intermediate interface where human-controlled quality screening has already ascertained the accuracy of the results,” the company observes. “Operating directly from the database provides two main benefits for users. The first is that the output is in real time or near real time, depending upon the frequency at which the data is refreshed. The second is that data anomalies are detected faster and are corrected in the database to prevent propagation of erroneous data. Our algorithms allow users to get to quality outputs faster than other competitive service offerings.” Nowigence is committed to helping individuals, teams and enterprises quickly distill knowledge from massive amounts of textual data, both public and private. By integrating state-of-the-art data processing techniques in an intuitive interface at an affordable subscription price, Pluaris puts the power of data science into the hands of consumers. For more information, visit the company’s website at www.Nowigence.com. NOTE TO INVESTORS: The latest news and updates relating to Nowigence are available in the company’s newsroom at https://ibn.fm/NOW

The Bitcoin Miami Kickoff Party taking place on Monday, April 4th, is the kickoff event for the reBLOCKmiami conference being held Tuesday, April 5th, at the Hilton Miami Airport Blue Lagoon, and is the perfect pre-conference kickoff atmosphere for making critical initial contacts while having a great time, especially if you are an entrepreneur, attorney, CPA, or investor in the Crypto, NFT, or De-Fi industry. The reBLOCKmiami conference focuses on the Real Estate Blockchain space, and the kickoff party is for anyone that wants to connect prior to the formal conference, on a fun and personal basis, with the movers and shakers in this sector. Industry insiders will be making deals and valuable connections. In fact, we ensure success by having ambassadors actively connecting you around. Everyone knows that connections made in a more personal environment are the most meaningful. A positive and fun setting allows communication at another level, building relationships and friendships that can last for years, in addition to providing a flow of rich information that can give you the inside track on what’s really happening. Some of the biggest and best deals can result from the most enjoyable and informal environments, so don’t miss out. The party event is being held at the popular Biscayne Bay Brewing Company in Miami, offering an atmosphere that includes great craft beers and appetizers. In addition, we’ve landed world-renowned DJ Wildstyle to ensure it all keeps going.  For individual passes visit https://ibn.fm/l3fze. For group discounts, email Andrew@FloridaBlockchainSummit.com.  For additional kickoff event information, visit https://ibn.fm/zdFwv.

• Easing federal regulations on cannabis will benefit cannabis companies
• Republican congresswoman says she has received assurances that her proposed cannabis bill will receive a hearing
• ACP operates in two states where cannabis is legal and is exploring expansion opportunities in additional states

Despite the House and Senate being controlled by the Democrats, Nancy Mace, a Republican representative from South Carolina, has said her proposed cannabis bill will get a hearing (https://ibn.fm/VWivR). Easing federal regulations on the substance, which Mace’s bill is designed to do, will benefit cannabis companies, including American Cannabis Partners (“ACP”), that are currently operating in states with legalized medical and recreational cannabis use. “As advocates push for congressional action on Democratic-led marijuana legalization bills in the House and Senate, a Republican congresswoman who’s championing an alternative reform measure says she has received assurances that there will be a hearing on her proposal even as a minority member of the chamber,” reported a “Marijuana Moment” article released earlier this month. “She also said that recent internal polling she’s done for her reelection campaign shows voters in her district are on her side when it comes to cannabis even as her primary election challenger and her own state party attack her reform efforts.” In the article, the status and anticipated progress of Mace’s States Reform Act (“SRA”) was discussed. “There was earlier reporting about Mace receiving assurances that Democratic leaders would hold a hearing on her bill,” the article stated. “But when asked whether that was contingent on a yes vote for a separate legalization bill—House Judiciary Committee Chairman Jerrold Nadler’s (D-NY) Marijuana Opportunity, Expungement and Reinvestment (‘MORE’) Act—the congresswoman said there was ‘no quid pro quo.’ “‘Personally, I want to respect the process, and MORE is going to come up again and let Democrats do the MORE Act. It’ll die in the Senate,’ she said. ‘And so when that’s done, we will do our hearing, and there was nothing done in exchange for it. I just made the ask, and we’re making it happen,’” the article quoted. “The congresswoman didn’t say when exactly she expects the hearing on her proposal, but it appears she expects it to happen sometime after a possible House floor vote on the MORE Act. Drug policy and civil rights groups sent a letter this week urging House leaders to schedule that vote to happen sometime this month.” The activity on the hill, while slow, appears to be movement in the right direction. Currently the use, sale and possession of cannabis with more than 0.3% THC is prohibited under the federal Controlled Substances Act of 1970, although a majority of states have taken the legalization of cannabis into their own hands. Currently cannabis use is legal for adults in 18 states and Washington, DC, with medical marijuana being legal in 38 states and DC (https://ibn.fm/7Ey0e). Cannabis companies around the country are watching this momentum closely, including American Cannabis Partners, which operates in Michigan and California. ACP is also in the process of exploring land acquisition and project development strategies for expanding operations to additional states. The company is focused on three business segments: real estate, acquisition and development of proprietary assets, and ongoing cultivation operations. Led by a seasoned management team with more than three decades of canna-business experience, ACP is guided by its strategy to capture opportunities in real estate and licensing in states that have recently passed cannabis legalization legislation, thereby equipping the company to capitalize on federal interstate commerce opportunities. For more information, visit the company’s website at www.ACPFarms.com. NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://ibn.fm/ACP